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Rambam Health Care Center, Haifa, IsraelAbstractMaximal antibiotic treatment for all patients suspected of harbouring a bacterial infection is non-viable, because it will rapidly induce
resistance and exhaust this ﬁnite resource. This raises two ethical dilemmas: the question of whether we are justiﬁed in increasing the
danger to a present, named, patient so as to beneﬁt future, unknown, patients; and whether we are allowed to do so without asking the
present patient for consent. Although the considerations for healthy elderly patients are similar to younger adults, the answers are
complex when addressing patients with dementia, severely reduced quality of life and at end of life. We argue that a public debate on the
balance between beneﬁt to a present patient versus harm to future patients should be conducted. Such a debate should include
examinations of scenarios in which antibiotic treatment does not gain any beneﬁt in a patient with infection: at the end of life; in
situations in which resistance is such that empirical antibiotic treatment seldom matches the susceptibilities of the pathogen; and in
patients with no quality of life. An explicit cost–beneﬁt model, incorporating quality of life and risk of resistance, in computerized
decision support might obviate a clinician’s need to deal with these difﬁcult issues at bedside.
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E-mail: leibovici@post.tau.ac.ilThe ethical dilemmasInappropriate empirical antibiotic treatment (one that does not
match the in vitro susceptibility of the pathogen) is associated
with a higher death rate in severe infections [1]. However, in
clinical practice, patients with suspected moderate to severe
bacterial infections are not given empirical antibiotic treatment
that would result in a maximum coverage rate [2]. Nor do
guidelines aim at 100% coverage with empirical treatment. The
reason is that maximum coverage would demand very broad-
spectrum antibiotic treatment (in many hospitals drugs of last
resort: a carbapenem drug plus vancomycin and maybe even
colistin). Such a policy is not sustainable: we have good grounds
to suspect that such a massive use of antibiotics of last resortClinical Microbiology and Infection © 2014 European Society of Cwould result in an immediate and sharp rise in resistance. This
will lead to inappropriate treatment for future patients and put
them at a higher risk for a fatal outcome and other adverse
outcomes. Hence, in daily practice we accept (a potential, small)
harm to a present patient to save antibiotics for future patients.
There are two ethical dilemmas underlying this practice: the
question whether we are justiﬁed in increasing the danger to a
present, named patient (even to a small degree) in order to
beneﬁt future patients; and whether we are allowed to do that
without asking the present patient for consent. In the previous
paper [3] we argued that future patients have a right to be
treated appropriately, and that squandering antibiotics that are
available now would infringe on this right (especially since the
development of new antibiotics is almost non-existent). We
based that on Locke’s Proviso, which is used to assess the
morality of using scarce resources [4] (to quote: ‘when a per-
son takes something from nature and makes it his own property
(by mixing it with his labour), one is allowed to do so only
where there is enough, and as good left in common for others’;
p. 288); and on the idea of justice between generations [5].Clin Microbiol Infect 2015; 21: 27–29
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tioners have a duty to preserve antibiotics for future patients.
‘Justice’ is included among the principals of the ‘Georgetown
mantra’ of bioethics (beneﬁcence, non-maleﬁcence, autonomy,
justice). The fair distribution of healthcare resources is one of
the principles of professionalism in medicine, and commitment
to just distribution of ﬁnite resources is one of the profession’s
commitments [6]. This article addresses the question of
balancing present against future patients, especially in the
context of elderly patients.The balance between present and future
patientsHow do we balance, quantitatively, beneﬁt to the present pa-
tient versus harm to future patients? There is little in the
bioethical discourse that can help us to achieve this balance [7].
Modern bioethics focus on the individual. There are two rea-
sons for that: mainly, modern bioethics developed in response
to unethical use of individuals by systems; and it developed at a
time when infections were seen mainly as a problem of the past.
Infection is the main area where the right of an individual is
balanced against the right of others: antibiotics, isolation and
quarantine, vaccination.
We could use a cost–beneﬁt or a cost–utility model to
attain this balance. It is not strange to incorporate cost–utility
analysis in ethical considerations: cost-effectiveness, cost–
beneﬁt and cost–utility analyses are strongly rooted in the
utilitarian framework of ethics [8]. This framework argues for
maximizing beneﬁt to all people. In a cost–beneﬁt or cost–
utility analysis we can count and quantify the beneﬁt to the
present patient: number of quality-adjusted life-years (QALYs)
bestowed by appropriate empirical antibiotic treatment (the
broader the spectrum of coverage, the larger the gain); versus
the cost of each antibiotic and its side-effects; and the cost (in
QALYs) to future patients because the change in resistance is
different for each antibiotic drug. We have shown that such a
model is feasible [9].
The use of a simplistic cost–utility model to decide on
antibiotic treatment raises unease when addressing the elderly
patient who is healthy and enjoys a good quality of life. Old
people have fewer QALYs to gain from appropriate antibiotic
treatment simply because of their age. But are we really
comfortable with the idea that an active 80-year-old patient will
be given a different antibiotic treatment than a 40-year-old
patient because of the difference in life expectancy? We know
that they are not interchangeable: each one is ‘…a unique being,
an end to itself and not the means to achieve some goal orClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectother’ (Kant in the Foundations of the Metaphysics of Morals). In
our cost–beneﬁt model of antibiotic treatment, we solved this
problem by assigning the same number of QALYs gained to all
patients with a life expectancy of more than a month if treated
appropriately [9].Patients for whom antibiotic treatment gains
very littleThe question is more difﬁcult in patients with severely reduced
quality of life or in patients with terminal dementia. The
considerations here are two-fold: reduced beneﬁt and
increased cost. Such patients gain less from antibiotic treat-
ment proportional to the decline in functional capacity,
cognitive function and quality of life. As such patients are
frequently exposed to the healthcare system they are more
likely to carry multidrug-resistant bacteria, necessitating
broader-spectrum empirical antibiotic treatment with higher
ecological costs.
People with dementia and low functional capacity are at
increased risk of infections. Treating them again and again with
broad-spectrum antibiotics leads in a short time to infections
caused by pathogens that are resistant to all antibiotics in
common use. The cost to society is also probably higher than
with younger or independent people because patients with
limited functional capacity are more likely to spread resistant
bacteria [10–13] and Clostridium difﬁcile [14,15].
Integrating these factors into a cost–beneﬁt model is
complicated and has not been attempted. In some countries and
societies a living will is acceptable: a person can ask to abstain
from some measures (e.g. resuscitation, feeding by tube or
antibiotic treatment) in the case he or she will not be able to
judge the necessity for that measure. Antibiotics are among the
interventions that people are ready to forgo in a living will
[16–18]. Education and discussion can affect advance health-
care decisions [19]. Where this discourse is possible, the dis-
cussion should include antibiotic treatment.
At the end of the spectrum are terminally ill patients, for
whom we are quite sure that no intervention would prolong
life, including antibiotics. Sub-groups of patients in whom anti-
biotics could not prolong life can be deﬁned [20]. In clinical
practice these patients are very frequently treated with antibi-
otics, especially at the very end of life [21]. Withholding anti-
biotics in this patient subgroup is not an established practice
[22]. We are not sure what the decision process is that
should guide antibiotic treatment for such patients [23]. Again,
a public discourse and consensus that antibiotics could be
withheld in such situations would be valuable.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 27–29
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(embedded in a utilitarian framework of ethics) allow the balance
between beneﬁt to the present patient given antibiotics and
harm to future patients because of resistance, they have yet to
offer guidance in the very old, in patients with limited quality of
life or with limited life expectancy. There is no clear-cut ethical
model that would help us there. The current strategy of ignoring
these difﬁcult considerations, in many locations worldwide, is
non-viable. Antibiotic use increases as end of life approaches
[21,22]. We witness the development of Gram-negative bacteria
resistant to carbapenems, enterococci resistant to vancomycin
and other difﬁcult-to-treat bacteria. By treating patients who do
not beneﬁt from antibiotics, we are harming patients who can be
cured and who can resume normal life following infection.
Detailed living wills, including questions on antibiotic treatment,
should solve part of this problem. A public debate, raising the
awareness of the public to the adverse ecological effects of
antibiotic treatment, would be helpful. Developing an explicit
model, incorporating quality of life and risk of resistance in the
beneﬁt and harm of antibiotic treatment might be a ﬁrst step to
approach the problem of antibiotic treatment towards the end
of life. An explicit cost–beneﬁt model incorporated in a decision
support system [9,24] can probably assist clinicians in these
difﬁcult decisions. Decisions on the collective are easier than
decisions made at the bedside. But the ﬁrst hurdle not yet
surmounted is to recognize that we have a problem with anti-
biotic treatment at end of life and that we need to open the
discussion despite the sensitivity of the topic.Transparency declarationThe authors declare that they have no conﬂicts of interest.References[1] Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Sys-
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